ADMA Biologics Inc (ADMA) Receives Average Rating of “Buy” from Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been assigned an average recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $10.92.

Several research analysts have commented on ADMA shares. Maxim Group set a $12.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of ADMA Biologics in a research note on Thursday, February 7th. Oppenheimer set a $13.00 price target on shares of ADMA Biologics and gave the stock a “buy adma” rating in a research note on Thursday, December 20th. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, WBB Securities raised shares of ADMA Biologics to a “buy” rating in a research note on Thursday, April 4th.

A number of large investors have recently added to or reduced their stakes in ADMA. Diag Capital Management LP bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $435,000. Renaissance Technologies LLC increased its position in shares of ADMA Biologics by 544.9% during the 3rd quarter. Renaissance Technologies LLC now owns 188,300 shares of the biotechnology company’s stock valued at $1,169,000 after purchasing an additional 159,100 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of ADMA Biologics by 54.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 81,003 shares during the last quarter. Delek Group Ltd. increased its position in shares of ADMA Biologics by 102.5% during the 4th quarter. Delek Group Ltd. now owns 118,539 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 60,000 shares during the last quarter. Finally, Vanguard Group Inc increased its position in shares of ADMA Biologics by 5.2% during the 3rd quarter. Vanguard Group Inc now owns 1,192,641 shares of the biotechnology company’s stock valued at $7,406,000 after purchasing an additional 58,610 shares during the last quarter. Institutional investors and hedge funds own 53.30% of the company’s stock.

ADMA stock opened at $5.24 on Friday. The company has a market cap of $236.86 million, a price-to-earnings ratio of -3.61 and a beta of 2.99. ADMA Biologics has a one year low of $2.08 and a one year high of $6.96. The company has a current ratio of 4.63, a quick ratio of 2.69 and a debt-to-equity ratio of 2.10.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.